Biogen CEO spells out interest in biotech buyout

Just days after scornfully assessing a field of weak-kneed pharma companies that were too timid to see the real value in Biogen Idec, the CEO says he may be in the market for a $10 billion acquisition himself. And in an interview with MergerMarkets he said that any takeover target would not have to have late-stage therapies in the pipeline. A bullish-sounding Jim Mullen also told the publication that he expects to see two new therapies launched this year from a pipeline with 15 compounds in Phase II or beyond. Mullen said Biogen Idec will focus on rheumatoid arthritis, lupus and leukemia.

- read the report from the Financial Times

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."